These findings suggest strong sex differences in Fmr1 knock-out mice, which translate to sex-associated differences in FXS patients, anticipating that future research of underlying kinase signaling in males and females could help to comprehend clinical benefits for all FXS patients [206]. The gene discussed is FMR1; the disease is fragile X syndrome.